Additionally, the 36-month beta value for CASI is 0.63. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CASI is 4.33M and currently, short sellers hold a 0.47% ratio of that float. The average trading volume of CASI on June 13, 2025 was 9.69K shares.
CASI) stock’s latest price update
CASI Pharmaceuticals Inc (NASDAQ: CASI)’s stock price has soared by 32.96 in relation to previous closing price of 1.79. Nevertheless, the company has seen a gain of 27.83% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-19 that BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), (“CASI” or the “Company”), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m.
CASI’s Market Performance
CASI Pharmaceuticals Inc (CASI) has experienced a 27.83% rise in stock performance for the past week, with a 24.61% rise in the past month, and a 6.97% rise in the past quarter. The volatility ratio for the week is 1.41%, and the volatility levels for the past 30 days are at 2.66% for CASI. The simple moving average for the past 20 days is 25.13% for CASI’s stock, with a -32.77% simple moving average for the past 200 days.
Analysts’ Opinion of CASI
Many brokerage firms have already submitted their reports for CASI stocks, with BTIG Research repeating the rating for CASI by listing it as a “Buy.” The predicted price for CASI in the upcoming period, according to BTIG Research is $4 based on the research report published on May 18, 2021 of the previous year 2021.
Mizuho, on the other hand, stated in their research note that they expect to see CASI reach a price target of $3.80. The rating they have provided for CASI stocks is “Buy” according to the report published on April 26th, 2021.
Oppenheimer gave a rating of “Outperform” to CASI, setting the target price at $5 in the report published on October 23rd of the previous year.
CASI Trading at 22.84% from the 50-Day Moving Average
After a stumble in the market that brought CASI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.97% of loss for the given period.
Stock Fundamentals for CASI
Current profitability levels for the company are sitting at:
- -1.38 for the present operating margin
- 0.39 for the gross margin
The net margin for CASI Pharmaceuticals Inc stands at -1.38. The total capital return value is set at -2.29. Equity return is now at value -1094.50, with -81.92 for asset returns.
The debt to equity ratio resting at 11.96. The interest coverage ratio of the stock is -716.11.
Currently, EBITDA for the company is -34.87 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 1.56. The receivables turnover for the company is 1.86for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.
Conclusion
In conclusion, CASI Pharmaceuticals Inc (CASI) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
